Financial Analysis: DNAPrint Genomics (OTCMKTS:DNAG) and Trevi Therapeutics (NASDAQ:TRVI)

DNAPrint Genomics (OTCMKTS:DNAG) and Trevi Therapeutics (NASDAQ:TRVI) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership.

Profitability

This table compares DNAPrint Genomics and Trevi Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DNAPrint Genomics	N/A	N/A	N/A
Trevi Therapeutics	N/A	-25.49%	-24.15%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for DNAPrint Genomics and Trevi Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DNAPrint Genomics	0	0	0	0	0.00
Trevi Therapeutics	1	0	9	2	3.00

Trevi Therapeutics has a consensus price target of $21.60, suggesting a potential upside of 88.81%. Given Trevi Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Trevi Therapeutics is more favorable than DNAPrint Genomics.

Institutional & Insider Ownership

95.8% of Trevi Therapeutics shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares DNAPrint Genomics and Trevi Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DNAPrint Genomics	N/A	N/A	N/A	N/A	N/A
Trevi Therapeutics	N/A	N/A	-$42.76 million	($0.32)	-35.75

Risk and Volatility

DNAPrint Genomics has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.

Summary

Trevi Therapeutics beats DNAPrint Genomics on 7 of the 9 factors compared between the two stocks.

About DNAPrint Genomics

DNAPrint Genomics, Inc. engages in the development and marketing of genetic testing products and services. It offers AncestryByDNA, a pan-chromosomal assay for genetic ancestry; EurasianDNA, which measures European sub-ancestry; EuropeanDNA, which reports a customer’s proportional basic continental European ancestry; DNAWitness to determine genetic heritage from DNA samples obtained from crime scenes; RETINOME, which provides a physical portrait of a person of interest for a detective based on a DNA sample from a crime scene or remains of an individual; RETINOME, which allows infer eye color from DNA; and GenomeLab SNPstream Genotyping System, which offers genotyping rates and uses a multiplexing format to generate data with the minimum of reagents. The company serves forensic science, genealogical research, consumer products, and pharmaceutical development clients. DNAPrint Genomics, Inc. was formerly known as Lexington Energy, Inc. The company was incorporated in 1983 and is based in Sarasota, Florida with a subsidiary in Leverkusen, Germany.

About Trevi Therapeutics

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.